drugset / Trial / NCT06209970
35kDa Hyaluronan Fragment Treatment of Colorectal and Rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
HA35 (Bioactive HA or B-HA or HA35) have good tissue permeability (B-HA injection, Ministry of Health, Registration number L20200708MP07707). HA35 might not lose HA's bioactivities of binding to a variety of hyaluronan's binding proteins or receptors, including the analgesic and anticancer effects of hyaluronan, therefore being named bioactive HA or B-HA (10) (B-HA injection, Ministry of Health, Registration number L20200708MP07707).
Timeline
- Start
- 2023-12-20
- Primary completion
- 2024-02-01
- Completion
- 2024-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sodium Hyaluronate | Other / unclassified | 5 mg/ml | Other |
Indications
No indication recorded.